TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and/or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 is used for the study of diseases associated with inappropriate angiogenesis
In Vitro
Angiopoieten 1 is a ligand for the endotheiium-specific receptor tyrosine kinase, TIE-2 is a novel angiogenic factor. Inhibition of TIE-2 is expected to serve to disrupt remodeling and maturation of new vasculature initiated by angiogenesis thereby disrupting the angiogenic process. Inhibition at the kinase domain binding site of VEGFR-2 would block phosphorylation of tyrosine residues and serve to disrupt initiation of angiogenesis. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
